An attenuated vaccine market is a type of vaccine produced by lessening the virulence of a pathogen, but still maintaining the state of viability. This process of attenuation initially gets an infectious agent and modifies it in order to make it harmless or less virulent. These vaccines are formed by raising the virus in tissue cultures that will go for less virulent strains. These vaccines are very different from those formed by killing the virus.
In an attenuated vaccine market, live virus particles possessing very low virulence is initially managed. They reproduce further in slow manner. Live attenuated vaccines comprise an adaptation of the living microorganism that has been made a little feeble in the lab so that it doesn’t bring about disease. As it is known that a live constricted immunization is the nearest thing to a characteristic contamination, these vaccines are considered as great "tutors" of the invulnerable framework.
They bring about solid cell and antibody reactions and frequently enduring protection with one or two dosages. It is said that attenuated vaccines cannot be employed by immunocompromised individuals. These vaccines help in initiating all the stages of the immune system and it also offers more durable immunity such that boosters are needed less frequently. Other advantages attached with it include its low cost, quick immunity, plus they are quite easy to transport or administer.
It has been anticipated that an advanced live attenuated vaccine may soon gain the potential to prevent a disease. Moreover, they can also be utilized for therapeutic purposes of an existing disease. Live attenuated vaccines Market size on the basis of types spans Measles, Polio, Smallpox, Rotavirus, Tuberculosis, Yellow fever, Varicella zoster, and Others. Market size on the basis of End Users spans hospitals clinics, and healthcare research institutes.
Live attenuated vaccines (LAV) Market size on the basis of product type spans Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, and MMR. Among all, the segment of pneumococcal disease is projected to take over the greatest share of the market globally, the reason being augmented occurrence of pneumococcal infections and the prerequisite for immunizations to avert the frequency of disease. Live attenuated vaccines Market size on the basis of application spans Pediatric, and Adult.
The global live attenuated vaccines Market size on the basis of geographical region spans North America, China, Europe, Japan, India, and Southeast Asia. As far as the geography is concerned, North America is the one that is dominating the market and is also simultaneously accounting for the largest share in the live attenuated vaccines market. Major companies operating in the global live attenuated vaccines market include Astellas Pharma Inc, MedImmune, LLC, Merck & Co, Pfizer, Sanofi Pasteur, Serum Institute, India Pvt. Ltd., GlaxoSmithKline, Johnson & Johnson, CSL Limited, and Emergent BioSolutions, Inc.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Live Attenuated Vaccines in these regions, from 2013 to 2025 (forecast), covering
• North America
• Southeast Asia
Global Live Attenuated Vaccines market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• QYH Biotech
• Kyoto Biken
• Ringpu Biology
• ChengDu Tecbond
• Sindh Poultry Vaccine Centre
• Merck Animal Health
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Companion Animals
• Livestock Animals
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Veterinary Clinics
• Veterinary Hospitals
Research Support Specialist, USA